CoChat
Sign Up
Cited by 66Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancerOvarian function and disorders

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer

Open access
Blagden, Sarah P.·2015·Frontiers in Oncology
DOI 10.3389/fonc.2015.00149PMC PMC4485078
Open this paper in CoChat — free accountOpen PDF

Abstract

Heterogeneity has emerged as a key feature of ovarian cancer between different ovarian cancer subtypes; within single ovarian cancer subtypes; and within individual patient tumors. At the genomic level, with the advent of ultra-deep sequencing technologies alongside RNA-Seq, epigenomics, and proteomics, the complexity surrounding heterogeneity has deepened. Here, we summarize the emerging understanding of heterogeneity in cancer as a whole and the key discoveries in this area relating to ovarian cancer. We explore the therapeutic limitations and possibilities posed by heterogeneity and how these will influence the future of ovarian cancer treatment and research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2015.00149

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. [1]Marusyk A Polyak K Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2010) 1805: 105– 17. 10.1016/j.bbcan.2009.11.002 19931353 PMC2814927 · DOI
  2. [2]Nowell PC The clonal evolution of tumor cell populations. Science (1976) 194: 23– 8. 10.1126/science.959840 959840 · DOI · Paper page
  3. [3]Iscove NN Senn JS Till JE McCulloch EA Colony formation by normal and leukemic human marrow cells in culture: effect of conditioned medium from human leukocytes. Blood (1971) 37: 1– 5. 5275755
  4. [4]Tomasson MH. Cancer stem cells: a guide for skeptics. J Cell Biochem (2009) 105: 745– 9. 10.1002/jcb.22050 19184979 · DOI
  5. [5]Polyak K Marusyk A Cancer: clonal cooperation. Nature (2014) 508: 52– 3. 10.1038/508052a 24695309 · DOI
  6. [6]Kreso A Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell (2014) 14: 275– 91. 10.1016/j.stem.2014.02.006 24607403 · DOI
  7. [7]Gillies RJ Verduzco D Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 12: 487– 93. 10.1038/nrc3298 22695393 PMC4122506 · DOI
  8. [8]Heppner GH Dexter DL DeNucci T Miller FR Calabresi P. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res (1978) 38: 3758– 63. 698935
  9. [9]Taparowsky E Suard Y Fasano O Shimizu K Goldfarb M Wigler M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature (1982) 300: 762– 5. 10.1038/300762a0 7177195 · DOI
  10. [10]International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature (2001) 409: 860– 921. 10.1038/35057062 11237011 · DOI · Paper page
  11. [11]Venter JC Adams MD Myers EW Li PW Mural RJ Sutton GG The sequence of the human genome. Science (2001) 291: 1304– 51. 10.1126/science.1058040 11181995 · DOI · Paper page
  12. [12]International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature (2004) 431: 931– 45. 10.1038/nature03001 15496913 · DOI · Paper page
  13. [14]Wood LD Parsons DW Jones S Lin J Sjöblom T Leary RJ The genomic landscapes of human breast and colorectal cancers. Science (2007) 318: 1108– 13. 10.1126/science.1145720 17932254 · DOI · Paper page
  14. [15]Wheeler DA Wang L. From human genome to cancer genome: the first decade. Genome Res (2013) 23: 1054– 62. 10.1101/gr.157602.113 23817046 PMC3698498 · DOI
  15. [16]Vogelstein B Papadopoulos N Velculescu VE Zhou S Diaz LA Jr Kinzler KW Cancer genome landscapes. Science (2013) 339: 1546– 58. 10.1126/science.1235122 23539594 PMC3749880 · DOI · Paper page
  16. [17]Gianni L Dafni U Gelber RD Azambuja E Muehlbauer S Goldhirsch A Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 12: 236– 44. 10.1016/S1470-2045(11)70033-X 21354370 · DOI
  17. [18]Bollag G Hirth P Tsai J Zhang J Ibrahim PN Cho H Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 467: 596– 9. 10.1038/nature09454 20823850 PMC2948082 · DOI
  18. [19]Murdoch D Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol (2008) 20: 104– 11. 10.1097/CCO.0b013e3282f44b12 18043264 · DOI
  19. [20]Teplinsky E Muggia F. Targeting HER2 in ovarian and uterine cancers: challenges and future directions. Gynecol Oncol (2014) 135: 364– 70. 10.1016/j.ygyno.2014.09.003 25220628 · DOI
  20. [21]McGranahan N Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell (2015) 27: 15– 26. 10.1016/j.ccell.2014.12.001 25584892 · DOI · Paper page
  21. [22]Wang V Li C Lin M Welch W Bell D Wong YF Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet (2005) 161: 170– 3. 10.1016/j.cancergencyto.2004.12.014 16102589 · DOI
  22. [23]Kurman RJ Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 34: 433– 43. 10.1097/PAS.0b013e3181cf3d79 20154587 PMC2841791 · DOI
  23. [24]Berchuck A Kohler MF Boente MP Rodriguez GC Whitaker RS Bast Jr Growth regulation and transformation of ovarian epithelium. Cancer (1993) 71: 545– 51. 10.1002/cncr.2820710209 8420675 · DOI
  24. [25]Lim D Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology (2013) 45: 229– 42. 10.1097/PAT.0b013e32835f2264 23478230 · DOI
  25. [26]Seidman JD Khedmati F. Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med (2008) 132: 1753– 60. 10.1043/1543-2165-132.11.1753 18976011 · DOI
  26. [27]Callahan MJ Crum CP Medeiros F Kindelberger DW Elvin JA Garber JE Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 25: 3985– 90. 10.1200/JCO.2007.12.2622 17761984 · DOI
  27. [28]Kindelberger DW Lee Y Miron A Hirsch MS Feltmate C Medeiros F Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol (2007) 31: 161– 9. 10.1097/01.pas.0000213335.40358.47 17255760 · DOI
  28. [29]Chene G Lamblin G Le Bail-Carval K Chabert P Bakrin N Mellier G. Early preinvasive lesions in ovarian cancer. Biomed Res Int (2014): 639252. 10.1155/2014/639252 24804229 PMC3997076 · DOI
  29. [30]Zeppernick F Meinhold-Heerlein I Shih IeM Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma–an update. J Obstet Gynaecol Res (2015) 41: 6– 11. 10.1111/jog.12550 25330822 PMC4352308 · DOI
  30. [31]Folkins AK Jarboe EA Saleemuddin A Lee Y Callahan MJ Drapkin R A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 108: 168– 73. 10.1016/j.ygyno.2008.01.012 18342932 PMC2746001 · DOI
  31. [32]Sirachý J An approach to the problem of heterogeneity of human tumour-cell populations. Br J Cancer (1979) 39: 570– 7. 10.1038/bjc.1979.103 486313 PMC2009909 · DOI
  32. [33]Ehlen T Dubeau L. Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene (1990) 5: 219– 23. 2320374
  33. [34]Lee JH Kavanagh JJ Wildrick DM Wharton JT Blick M. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res (1990) 50: 2724– 8. 2328498
  34. [35]Stronach EA Sellar GC Blenkiron C Rabiasz GJ Taylor KJ Miller EP Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. Cancer Res (2003) 63: 8648– 55. 14695176
  35. [36]Rhei E Bogomolniy F Federici MG Maresco DL Offit K Robson ME Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res (1998) 58: 3193– 6. 9699640
  36. [37]Okamoto A Sameshima Y Yokoyama S Terashima Y Sugimura T Terada M Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res (1991) 51(19): 5171– 6. 1680546
  37. [38]Khalique L Ayhan A Weale ME Jacobs IJ Ramus SJ Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol (2007) 211: 286– 95. 10.1002/path.2112 17154249 · DOI
  38. [39]Kandoth C McLellan MD Vandin F Ye K Niu B Lu C. Mutational landscape and significance across 12 major cancer types. Nature (2013) 502: 333– 9. 10.1038/nature12634 24132290 PMC3927368 · DOI · Paper page
  39. [40]Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474: 609– 15. 10.1038/nature10166 21720365 PMC3163504 · DOI · Paper page
  40. [41]Malek JA Mery E Mahmoud YA Al-Azwani EK Roger L Huang R Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One (2011) 6: e28561. 10.1371/journal.pone.0028561 22194851 PMC3237432 · DOI
  41. [42]McBride DJ Etemadmoghadam D Cooke SL Alsop K George J Butler A Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol (2012) 227: 446– 55. 10.1002/path.4042 22514011 PMC3428857 · DOI
  42. [44]Tothill RW Tinker AV George J Brown R Fox SB Lade S Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 14: 5198– 208. 10.1158/1078-0432.CCR-08-0196 18698038 · DOI
  43. [45]Leong HS Galletta L Etemadmoghadam D George J Australian Ovarian Cancer Study Köbel M Efficient molecular subtype classification of high-grade serous ovarian cancer. J Pathol (2015) 236: 272– 7. 10.1002/path.4536 25810134 · DOI
  44. [46]Gerlinger M Quezada SA Peggs KS Furness AJ Fisher R Marafioti T Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol (2013) 231: 424– 32. 10.1002/path.4284 24122851 PMC4241038 · DOI
  45. [47]Emerson RO Sherwood AM Rieder MJ Guenthoer J Williamson DW Carlson CS High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol (2013) 231: 433– 40. 10.1002/path.4260 24027095 PMC5012191 · DOI
  46. [48]Hoogstraat M de Pagter MS Cirkel GA van Roosmalen MJ Harkins TT Duran K Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res (2014) 24: 200– 11. 10.1101/gr.161026.113 24221193 PMC3912411 · DOI
  47. [50]Gerlinger M Rowan AJ Horswell S Larkin J Endesfelder D Gronroos E Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 366: 883– 92. 10.1056/NEJMoa1113205 22397650 PMC4878653 · DOI · Paper page
  48. [51]Bashashati A Ha G Tone A Ding J Prentice LM Roth A Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 231: 21– 34. 10.1002/path.4230 23780408 PMC3864404 · DOI
  49. [52]Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 72: 4875– 82. 10.1158/0008-5472.CAN-12-2217 23002210 PMC3712191 · DOI · Paper page
  50. [53]Schwarz RF Ng CK Cooke SL Newman S Temple J Piskorz AM Phylogenetic quantification of intra-tumor heterogeneity predicts time to relapse in high-grade serous ovarian cancer. PLoS Med (2015) 12: e1001789. 10.1371/journal.pmed.1001789 25710373 PMC4339382 · DOI
  51. [54]Hayes DF Paoletti C. Circulating tumour cells: insights into tumour heterogeneity. J Intern Med (2013) 274(2): 137– 43. 10.1111/joim.12047 23844916 · DOI

Cited by

Sorted by citations

Metadata

Authors
Blagden, S. P.
Affiliations
Churchill Hospital (GB)
Corresponding author
Blagden, Sarah P.
ORCID
Blagden, Sarah P.
Venue
Frontiers in Oncology
Publisher
Frontiers Media SA
Published
2015-06-30
Volume
5
Pages
149-149
ISSN
2234-943X (ISSN-L)
DOI
10.3389/fonc.2015.00149
PMC
PMC4485078
OpenAlex
W1486589243
Cited by
66
References
5
Citations by year
2026: 5 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 8 · 2017: 8 · 2016: 10 · 2015: 2
FWCI
1.42
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
ovarian cancer, tumor heterogeneity, intratumoral heterogeneity, subtypes, genomic heterogeneity, epigenomics, proteomics, RNA-seq, treatment resistance, precision oncology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review